Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement

Related Keywords

Molly Mccully ,Kevin Hern ,Ajay Nirula ,Eli Lilly ,Carolyn Bertozzi ,Liz Melone ,Exchange Commission ,Lycia Therapeutics Inc ,Stanford University ,Lycia Therapeutics ,Aetna Wun Trombley ,Generally Accepted Accounting Principles ,South San Francisco ,Private Securities Litigation Reform Act ,Lilly Media ,Lilly Investors ,Lycia Media ,Nyse Lly ,Indiana ,Midwest ,United States Of America ,North America ,California ,West Southwest ,Collaboration ,Herapeutics ,Conomics ,Medicine ,Ommerce ,Inance ,Stock Exchange ,Ommercialization ,Expectation ,Ycia Therapeutics Inc ,Research ,